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Background: Right ventricular failure (RVF) following left ventricular assist device (LVAD) implantation is associated with morbidity and mortality. 
Our purpose is to validate the right ventricular failure risk score (RVFRS) proposed by University of Michigan in a large cohort of patients supported 
with an LVAD from a single center.
Methods: RVF was defined as one or more of the following: need for right ventricular assist device, use of inotropes > 14 days, or use of inhaled 
nitric oxide > 48 hours. The RVFRS includes 4 pre-operative weighted variables: vasopressor requirement (4 points), creatinine ≥ 2.3 mg/dl (3 
points), bilirubin ≥ 2.0 mg/dl (2.5 points) and AST ≥ 80 IU/I (2 points). The RVFRS was applied retrospectively in 421 patients supported with an 
LVAD (56 continuous flow pumps and 365 pulsatile pumps) and stratified into categories: ≤ 3.0, 4.0-5.0 and ≥ 5.5.
Results: A total of 199 (47.3%) had RV failure following LVAD implantation. The area under the curve (AUC) for the RVFRS was 0.675 (0.623, 
0.726). Post-operative RVF was present in 26 (49%) of patients with a continuous flow pump and 173 (47%) in patients supported with a pulsatile 
device (p=0.9).
Conclusions: The RVFRS may be used to estimate the risk of RVF following LVAD implantation. There was no difference in post-operative RVF in 
patients supported with a continuous flow vs. pulsatile flow LVAD. These findings may have important implications on patient selection regarding 
mechanical circulatory support for end-stage heart failure patients.
RVFRS N (%) RVF, N(%) No RVF, N(%) OR(95%CI) vs. ≤ 3.0 OR(95%CI) vs. 4.0-5.0 Sensitivity (%) Specificity (%)
≤3.0 248(59) 91(37) 157(63) 54 71
4.0-5.0 66(16) 32(48) 34(52) 1.62(0.94,2.81)
≥5.5 107(25) 76(71) 31(29) 4.23(2.59,6.91) 2.6(1.38,4.93) 38 86
